Print the page
Increase font size

Posted September 16, 2020

Byron King

By Byron King

Problem or Opportunity?

If you recall, on Monday we featured a very discouraged business owner -- understandably so. We received the following email in response

I saw your readers comment about losing his business in the event industry due to the lockdowns. I work in the event industry as well, so his concerns hit close to home. For me, there is work to do; the answer is very clear, adapt or die.

Without knowing what area of the industry the reader works in, here is what I am considering:

  1. What makes new work from home adaptations work for companies?
    • Reduced travel costs. Efficient use of time. Flexibility to mix the conference with daily work. No walk of shame to leave a crowded seminar room in the middle of a boring presentation.

  1. Whats the downside to working from home?

    • Death by powerpoint or sleep-inducing presentations. No chance meetings over coffee or meeting old colleagues. No sidebar conversations with experts. And for some, no travel, no evening dinners or sponsored events no fun!
    • I think 2021 will be a rebuilding period because of the downside listed above, and 2022 will be a fantastic year for the event industry as attendees will be enthusiastic about getting back to seeing long time friends, colleagues and mentors. In person!

      Every business needs to find its own list and adapt or, as the reader says, cash-out. But the bigger the problem, the bigger the opportunity you get to decide.

      Keep your ideas coming, readers. How are you adapting -- business or otherwise -- to survive 2020?

      Send your opinions to,

      Your Rundown for Wednesday, Sept. 16, 2020

      Vaccine War

      The federal government outlined a sweeping plan Wednesday to make vaccines for COVID-19 available for free to all Americans, the Associated Press reports.

      Federal agencies along with the Defense Department unveiled a playbook to Congress for delivering vaccines to state and local governments by January or even sooner, with the Pentagon being partly responsible for distributing the vaccines.

      At present, the plan seems more of a campaign to win over Americans to the idea of a COVID-19 vaccine (think PSAs).

      Is a vaccine sought-after? Sure but many Americans question the safety -- not to mention efficacy -- of potential vaccines, regardless of FDA approval.

      (You read that correctly: vaccines plural. The federal governments plan indicates free vaccines from multiple manufacturers.)

      According to an Associated Press poll in May, about half of Americans surveyed said they would get vaccinated, 1 in 5 said they would not get vaccinated and about 30% said they were undecided.

      The Rundowns taking an informal poll: Would you get vaccinated when it becomes available? Why or why not?

      Market Rundown for Wednesday, Sept. 16, 2020

      S&P 500 futures are up 12 points to 3,413.

      Oil is up 2.5% to $39.22 for a barrel of West Texas crude.

      Gold is up $6.80 per ounce to $1,973.00.

      Bitcoins up $176.25 to $10,936.29.

      Send your comments and questions to,

      Have a fantastic Wednesday! Well have more to say at the end of the week.

      For the Rundown,

      Aaron Gentzler

      Aaron Gentzler

      $1,000 Sign Up Bonus To Work Part-Time at an Arcade

      Posted June 18, 2021

      By Aaron Gentzler

      Today we take a look at Ford’s recent run of good fortune and forecast what could come next for the stock. We also feature a reader letter about wages and the free market.
      A Meme Stock ETF

      A Meme Stock ETF

      Posted June 16, 2021

      By Aaron Gentzler

      We think an ETF pegged exclusively to meme stocks must be in the works. We’re calling it now…

      Novavax: Competitive Advantages ‘Boost’ Profits

      Posted June 14, 2021

      By Aaron Gentzler

      Novavax announced its Covid-19 vaccine… So what’s next for the Maryland-based biotech company?
      Make America Competitive Again

      Make America Competitive Again

      Posted June 11, 2021

      The Senate passed the U.S. Innovation and Competition Act (USICA). The bill aspires to make America competitive again… and takes aim at China.
      Biogen Breaks Through 5-Year Stalemate

      Biogen Breaks Through 5-Year Stalemate

      Posted June 09, 2021

      “This could be a key moment for the biotech sector,” says our chief market analyst Greg Guenthner.
      Small Business Taxed for Pandemic Shortfalls

      Small Business Taxed for Pandemic Shortfalls

      Posted June 07, 2021

      By Aaron Gentzler

      Small businesses -- hanging on by a thread -- are being taxed for pandemic shortfalls…